Published in Addict Biol on November 04, 2010
Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol (2000) 2.29
Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat (2001) 1.68
Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry (1999) 1.59
Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry (2006) 1.52
Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med (1996) 1.51
Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry (2005) 1.48
Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance. Anesthesiology (1992) 1.46
Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med (2009) 1.29
Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport (1994) 1.28
Amphetamine administered to the ventral tegmental area but not to the nucleus accumbens sensitizes rats to systemic morphine: lack of conditioned effects. Brain Res (1990) 1.19
Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. J Pain Symptom Manage (1994) 1.13
Cocaine alters opiate receptor binding in critical brain reward regions. Synapse (1989) 1.01
Brain mu-opioid receptor binding: relationship to relapse to cocaine use after monitored abstinence. Psychopharmacology (Berl) (2008) 0.97
Chronic repeated cocaine administration alters basal and opioid-regulated adenylyl cyclase activity. Synapse (1993) 0.96
Mu opiate receptors are selectively labelled by [3H]carfentanil in human and rat brain. Eur J Pharmacol (1989) 0.96
Cocaine metabolism in human fetal and adult liver microsomes is related to cytochrome P450 3A expression. Life Sci (2000) 0.95
Opioid-induced pruritus: an update. Clin Exp Dermatol (2009) 0.94
Regulation of opioid receptors by cocaine. Ann N Y Acad Sci (2001) 0.92
Cocaine alters mu but not delta or kappa opioid receptor-stimulated in situ [35S]GTPgammaS binding in rat brain. Synapse (2003) 0.91
Continuous cocaine administration enhances mu- but not delta-opioid receptor-mediated inhibition of adenylyl cyclase activity in nucleus accumbens. Eur J Pharmacol (1996) 0.89
Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology (1996) 0.88
Adaptive changes in the proenkephalin and D2 dopamine receptor mRNA expression after chronic cocaine in the nucleus accumbens and striatum of the rat. Eur Neuropsychopharmacol (1995) 0.87
Long-term cocaine self-administration decreases striatal preproenkephalin mRNA in rhesus monkeys. Pharmacol Biochem Behav (1997) 0.85
Effect of opioid peptides on dopamine release from nucleus accumbens after repeated treatment with methamphetamine. Eur J Pharmacol (1994) 0.85
"Binge" cocaine differentially alters preproenkephalin mRNA levels in guinea pig brain. Brain Res Bull (2003) 0.80
Reduced duration of intrathecal sufentanil analgesia in laboring cocaine users. Anesth Analg (2003) 0.77
Investigations with the specific mu-opiate receptor agonist fentanyl in depressive patients: growth hormone, prolactin, cortisol, noradrenaline and euphoric responses. Neuropsychobiology (1989) 0.77
Sensitization does not develop to cocaine-induced potentiation of the antinociceptive effect of morphine. Brain Res Bull (2002) 0.77
Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med (2010) 7.83
Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med (2004) 4.55
Why should addiction medicine be an attractive field for young physicians? Addiction (2008) 3.52
Introduction to behavioral addictions. Am J Drug Alcohol Abuse (2010) 3.22
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res (2008) 2.62
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis (2008) 2.30
Use of a 'microecological technique' to study crime incidents around methadone maintenance treatment centers. Addiction (2012) 2.20
Elevated airborne exposures of teenagers to manganese, chromium, and iron from steel dust and New York City's subway system. Environ Sci Technol (2004) 2.18
Opiate versus psychostimulant addiction: the differences do matter. Nat Rev Neurosci (2011) 2.05
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis (2008) 1.94
Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict (2006) 1.94
Endovascular repair of aortic aneurysm in patients physically ineligible for open repair. N Engl J Med (2010) 1.92
The Fagerstrom Test for Nicotine Dependence and the Diagnostic Interview Schedule: do they diagnose the same smokers? Addict Behav (2002) 1.74
Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol (2012) 1.71
Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther (2010) 1.70
Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clin Chem (2013) 1.67
Cocaine craving and use during daily life. Psychopharmacology (Berl) (2009) 1.62
On-site test for cannabinoids in oral fluid. Clin Chem (2012) 1.57
Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry (2005) 1.48
Effect of race on the timing of the Glenn and Fontan procedures for single-ventricle congenital heart disease. Pediatr Crit Care Med (2012) 1.48
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther (2004) 1.46
The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) (2009) 1.42
Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend (2009) 1.42
Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend (2010) 1.39
Questions on conflict of interest. Am J Psychiatry (2010) 1.38
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) (2007) 1.32
Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit (2008) 1.29
A factor analysis of the Fagerström Test for Nicotine Dependence (FTND). Nicotine Tob Res (2003) 1.28
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem (2009) 1.28
Steel dust in the New York City subway system as a source of manganese, chromium, and iron exposures for transit workers. J Urban Health (2005) 1.26
Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. Am J Addict (2006) 1.21
Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend (2005) 1.20
Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [(11)C]P943 in humans. J Cereb Blood Flow Metab (2009) 1.19
Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem (2010) 1.19
Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem (2011) 1.18
PET imaging of opioid receptors in pain: progress and new directions. Curr Pharm Des (2004) 1.17
Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem (2014) 1.15
Statins and other cholesterol-lowering medications and the presence of glaucoma. Arch Ophthalmol (2004) 1.15
Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology (2007) 1.14
Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem (2012) 1.09
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
State of the art treatments for cannabis dependence. Psychiatr Clin North Am (2012) 1.07
Calorie restriction increases cigarette use in adult smokers. Psychopharmacology (Berl) (2004) 1.06
The second-oldest state psychiatric hospital in the United States. Am J Psychiatry (2014) 1.06
Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. Biol Psychiatry (2010) 1.05
Pharmacological treatment of cannabis dependence. Curr Pharm Des (2011) 1.04
ADP-specific sensors enable universal assay of protein kinase activity. Chem Biol (2004) 1.04
Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Test Anal (2014) 1.03
Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol (2008) 1.01
Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. J Anal Toxicol (2006) 1.01
Strategies for quitting among non-treatment-seeking marijuana smokers. Am J Addict (2005) 1.00
Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methods. Nucl Med Biol (2003) 0.99
Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects. Int J Neuropsychopharmacol (2012) 0.99
A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics (2014) 0.99
Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction (2010) 0.98
Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal. Am J Drug Alcohol Abuse (2010) 0.98
Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis. Clin Chim Acta (2012) 0.97
Brain mu-opioid receptor binding: relationship to relapse to cocaine use after monitored abstinence. Psychopharmacology (Berl) (2008) 0.97
Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug Alcohol Depend (2011) 0.97
Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. Addict Biol (2008) 0.96
Longitudinal ECG changes in cocaine users during extended abstinence. Drug Alcohol Depend (2008) 0.95
Cannabinoid stability in authentic oral fluid after controlled cannabis smoking. Clin Chem (2012) 0.95
Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects. Alcohol Clin Exp Res (2011) 0.94
Social determinants of health: an economic perspective. Health Econ (2009) 0.94
Non-β-cell progenitors of β-cells in pregnant mice. Organogenesis (2010) 0.94
Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J Anal Toxicol (2012) 0.93
Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium. J Nucl Med (2009) 0.92
Regional mu-opioid receptor binding in insular cortex is decreased in bulimia nervosa and correlates inversely with fasting behavior. J Nucl Med (2005) 0.92
Naloxone-induced cortisol predicts mu opioid receptor binding potential in specific brain regions of healthy subjects. Psychoneuroendocrinology (2011) 0.92
Recurrent delirium after surgery for congenital heart disease in an infant. Pediatr Crit Care Med (2011) 0.92
An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov (2011) 0.91
Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. Anal Bioanal Chem (2013) 0.91
Cost-effectiveness analysis of treatments for chronic disease: using R to incorporate time dependency of treatment response. Med Decis Making (2005) 0.91
Histological criteria for grading of atypia in melanocytic conjunctival lesions. Pathology (2008) 0.91
Intravenous butyrylcholinesterase administration and plasma and brain levels of cocaine and metabolites in rats. Eur J Pharmacol (2005) 0.90
Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration. Anal Bioanal Chem (2011) 0.90
Differential effects of trabecular meshwork stiffness on outflow facility in normal human and porcine eyes. Invest Ophthalmol Vis Sci (2012) 0.89
Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers? Clin Chem (2013) 0.89
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res (2011) 0.89
Economic evaluation of coronary artery bypass grafting surgery with and without cardiopulmonary bypass: cost-effectiveness and quality-adjusted life years in a randomized controlled trial. Artif Organs (2008) 0.89
EEG absolute power during extended cocaine abstinence. J Addict Med (2007) 0.89
Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology (Oxford) (2011) 0.87
Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metab Rev (2015) 0.87
Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration. Clin Chem (2011) 0.86
Motivations to quit cannabis use in an adult non-treatment sample: are they related to relapse? Addict Behav (2013) 0.86
Spending of remuneration by subjects in non-treatment drug abuse research studies. Am J Drug Alcohol Abuse (2006) 0.85
Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. Am J Addict (2014) 0.84
Cannabis withdrawal in chronic cannabis users with schizophrenia. J Psychiatr Res (2012) 0.84
Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Med Decis Making (2005) 0.84
In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis. Anal Bioanal Chem (2013) 0.84
Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. J Anal Toxicol (2009) 0.84
Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects. Addict Biol (2012) 0.84
MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration. Ther Drug Monit (2011) 0.84
Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat (2005) 0.84
Circumferential tensile stiffness of glaucomatous trabecular meshwork. Invest Ophthalmol Vis Sci (2014) 0.83
Sociodemographic characteristics associated with substance use status in a trauma inpatient population. J Addict Dis (2007) 0.83
Risk of psychoactive substance dependence among substance users in a trauma inpatient population. J Addict Dis (2007) 0.82
The crystal structure of a constitutively active mutant RON kinase suggests an intramolecular autophosphorylation hypothesis. Biochemistry (2010) 0.82